The Power of Innovation Centres in US Healthcare

By Staff Writer

November 4, 2023

Unveiling the Potential of Healthcare Innovation Centres


A growing trend in US healthcare systems, innovation centres are creating waves in the sector. These centres, which prioritise the quick creation, operationalisation, and assessment of novel innovations—many of which are digital—are transforming the healthcare industry. They are usually developed in response to issues that healthcare systems encounter, with a shared emphasis on problem-solving and real-time healthcare delivery.

These centres focus on three main areas: rapidly testing, assessing, and scaling domestic initiatives; disseminating creative, effective ideas throughout the healthcare system; and creating new solutions and ideas from data, experiences, and activities. Innovation centres can provide excellent, hyperlocal research and quality improvement when they are operating at peak efficiency.



The Success and Sustainability of Innovation Centres


However, it’s estimated that up to 90% of industry innovation centres fail. Despite this, healthcare innovation centres have seen significant growth in the past decade. The key to their success and sustainability lies in how they define their value and success.


Innovation centres often focus on demonstrating value in a creative way, rather than commercialisation of innovations. They add value to their institutions through their projects and innovations. For instance, they may create a decision support tool in the electronic health record to identify patients who smoke upon hospital admission. This not only benefits the patients but also the institution by meeting quality metrics.

These centres also offer value by “failing fast”, spending less money to understand whether a project or innovation will or will not work. This sets them apart from the wider healthcare organisation, which tends to be slower and more cautious.

Centres for healthcare innovation can become sustainable entities within US healthcare institutions. However, they must work effectively with their institutions to define success more broadly than purely financial return on investment. The field needs to develop more robust means of measuring these nonfinancial benefits for long-term success.

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.